Cargando…
Suboptimal concordance in testing and retesting results of triple-negative breast carcinoma cases among laboratories: one institution experience
BACKGROUND: Triple-negative breast carcinoma (TNBC) patients do not benefit from hormone- or human epidermal growth factor receptor 2- (HER2-) targeted therapies. Accurate testing is pivotal for these patients. METHODS: TNBC cases that were retested at our institution during a 3-year period were eva...
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
BioMed Central
2019
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6788018/ https://www.ncbi.nlm.nih.gov/pubmed/31632197 http://dx.doi.org/10.1186/s12935-019-0987-7 |